Andrew Armstrong

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Andrew Armstrong

Aug 24, 2024, 12:41 | Insight

Nima Sharifi: HSD3B1 and outcomes with ADT+enzalutamide in ARCHES

Nima Sharifi, Scientific Director, Desai Sethi Urology Institute, at University of Miami Miller School of…

Jul 19, 2024, 22:57 | Insight

Andrew Armstrong: WNT pathway alterations in prostate cancer

Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology at the Duke Cancer Institute,…

May 24, 2024, 15:23 | Blog

Neeraj Agarwal: Join us for the Research To Practice Prostate Cancer program on ASCO24

Sumanta Pal shared a post by Neeraj Agarwal on X/Twitter: "With Neeraj Agarwal on the program,…

May 20, 2024, 14:23 | Blog

Shahla Bari: Duke’s 1st Kidney cancer and microbiome symposium

Shahla Bari, Assistant Professor of Medicine at Duke Cancer Institute, shared on X/Twitter: "Brilliant minds coming…

Apr 30, 2024, 11:54 | Societies

15 Posts Not To Miss from APCCC24!

The Advanced Prostate Cancer Consensus Conference 2024 (APCCC24) was held from April 25th to April…

Dec 15, 2023, 06:25 | Drugs

Andrew Armstrong: Pleased to share our ARCHES analysis of efficacy, safety, and QOL of enza/ADT in men w/mHSPC by age

Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology at the Duke Cancer Institute,…

All: 6 Posts: 1 - 100